Exalenz Bioscience Ltd. (TASE:EXEN) today reported positive results in the preliminary trial of its BreathID non-invasive device for the detection of hepatocellular carcinoma, a type of liver cancer. On the basis of the results, the company plans to begin a larger trial of the device for this indication.
The trial included 36 patients at Hadassah Medical Organization's Ein Kerem Hospital in Jerusalem. The patients were first checked by ultrasound, and those suspected of liver cancer underwent CT or MRI tests, which found that 26 patients had the disease. All the patients were then given breath tests with the BreathID device to test whether it could achieve similar statistically meaningful results. The device achieved a congruence of 93%.
Exalenz is preparing a clinical trial and will shortly submit protocols to the US Food and Drug Administration (FDA) and the Ministry of Health in Israel and Canada. This trial will include 100 patients at five hospitals in Israel, the US, and Canada.
Exalenz's share price rose 6.2% in morning trading to NIS 0.87, giving a market cap of NIS 110 million.
Published by Globes [online], Israel business news - www.globes-online.com - on July 24, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011